Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial inpatients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics and immunogenicity of ABY-035

Next Previous
Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial inpatients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics and immunogenicity of ABY-035

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Izokibep (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Sponsors ACELYRIN; Affibody

Most Recent Events

  • 27 Nov 2023 According to an ACELYRIN media release, data from this trial were presented at the American College of Rheumatology annual meeting.
  • 15 Nov 2023 Results assessing data from baseline to 46 weeks on arthritis and skin composite efficacy endpoints and longer-term safety, presented at the ACR Convergence 2023.
  • 15 Nov 2023 Results of izokibep treatment to week 46 on patient-reported outcomes (PROs), following a 16-week placebo-controlled period presented at the ACR Convergence 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top